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Abstract
Objectives Using the human telomerase reverse transcriptase
(hTERT) promoter and the modified ferritin heavy chain (Fth)
reporter gene, reporter gene expression for MRI was exam-
ined in telomerase positive and negative tumour cells and
xenografts.
Methods Activity of the reporter gene expression vector
Lenti-hTERT-Fth1-3FLAG-Puro was compared to constitu-
tive CMV-driven expression and to the untransfected parental
control in five tumour cell lines: A549, SKOV3, 293T, U2OS
and HPDLF. In vitro, transfected cells were evaluated for
FLAG-tagged protein expression, iron accumulation and
transverse relaxation. In vivo, tumours transduced by
lentiviral vector injection were imaged using T2*WI.
Changes in tumour signal intensity were validated by
histology.
Results Only telomerase positive tumour cells expressed
FLAG-tagged Fth and displayed an increase in R2* above
the parental control, with a corresponding change in T2*WI.
In addition, only telomerase positive tumours, transduced by
injection of the reporter gene expression construct, exhibited a
change in signal intensity on T2*WI. Tumour histology veri-
fied the expression of FLAG-tagged Fth and iron accumula-
tion in telomerase positive tissue.
Conclusion Reporter gene expression for MRI, using the Fth
reporter and the hTERT promoter, may be a useful strategy for
the non-invasive diagnosis of many types of cancer.
Key points
•Modified heavy chain of ferritin can serve as anMR reporter
gene
• hTERT promoter can direct the expression of reporter gene
in cancer cells
• MR reporter imaging mediated by hTERT promoter can be
used for cancer diagnosis
Keywords Magnetic resonance imaging . Neoplasm .
hTERT . Reporter gene expression . Ferritin heavy chain
Abbreviations
CMV Cytomegalovirus
ELISA Enzyme-linked immunosorbent assay
FAC Ferric ammonium citrate
FSE Fast spin echo
Fth Ferritin heavy chain
hTERT Human telomerase reverse transcriptase
GRE Gradient recalled echo
MRI Magnetic resonance imaging
TE Time to echo




Telomerase is a ribonucleoprotein enzyme that controls the
elongation of telomeres in mammalian cells [1]. It is usually
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approximately 85 % of human cancer cells, which maintain
telomerase activity to sustain proliferation [2]. The selective
reactivation of telomerase in cancer cells offers an attractive
target for cancer diagnosis. Human telomerase reverse tran-
scriptase (hTERT) is the catalytic subunit of telomerase, and a
strong correlation is observed between telomerase activity and
hTERT mRNA expression in a variety of cancers [3]. Many
researchers designed reporter gene imaging formulations in
which promoter fragments of hTERT were used to direct the
expression of reporter genes [4]. These encoded for proteins
that change MRI contrast, bind radiolabelled probes or emit
light [5, 6]. By introducing the gene expression system into
cells using molecular techniques, the reporter gene of choice
was (over)expressed only in telomerase-positive tumour cells
as demonstrated in vitro and in vivo by position emission
tomography (PET) or charge-coupled device (CCD) camera
using reporter genes such as the Na/I symporter (NIS) [7] or
the green fluorescence protein (GFP) [8].
MRI has been widely used in the field of modern medical
diagnosis and treatment. Compared with optical imaging and
nuclear medicine modalities, MRI has the advantages of
multi-parameter imaging, higher spatial and temporal resolu-
tion, and lack of ionizing radiation. The primary requirement
for an MR reporter gene is to provide contrast that can be
distinguished from the non-transgenic cells [9]. Ferritin is an
iron storage protein, which can accumulate significant
amounts of hydrous ferric oxide iron from the intracellular
labile iron pool, and then store it as ferrihydrite [10]. The
expression of ferritin causes the transverse relaxation rate of
transfected cells to increase significantly and generate strong
hypointensity on T2 /T2*-weighted images [10].
In the present study, we hypothesized that telomerase-
positive tumours and cells would be visualized by MR imag-
ing using the hTERT promoter and the modified ferritin heavy
chain (Fth) reporter gene. To test our hypothesis, we generated
recombinant lentivirus Lenti-hTERT-Fth1-3FLAG-Puro in
which the hTERT promoter was used to direct the expression
of the modified Fth reporter gene, and then the recombinant
vectors were transduced into cells in vitro and injected into
tumour models in nude mice. Our aim was to assess the po-
tential application of MR reporter imaging, mediated by the
hTERT promoter, to cancer diagnosis.
Materials and methods
Construction and production of lentiviral vectors
The ferritin heavy chain (Fth1) gene was synthesized by
Shanghai Generay Biotech Co., Ltd according to the Fth1
gene sequence in GenBank (NM_010239) with the exclusion
of regulatory iron response elements, and then tagged with
three consecutive FLAG sequence (3FLAG). The construct
was subcloned into the NheI and BamHI restriction sites in
the lentiviral vector pCDH-CMV-MCS-Puro to form the
pCDH-CMV-Fth1-3FLAG-Puro vector. The pCDH-CMV-
Fth1-3FLAG-Puro vector was linearized by restriction digest
with SpeI and XbaI, and purified to remove the CMV promoter
fragment. Polymerase chain reaction (PCR) was used to amplify
the hTERT promoter from plasmid pLenti-hTERT-EGFP, a gift
from Mr Li (Department of Pathophysiology, Third Military
Medical University, Chongqing, China), using forward primer
5 ′ - TTTTATCGATACTAGTCACAGACGCCCA
GGACCGCGCTTC-3 ′ and r e v e r s e p r ime r 5 ′ -
ATTCGCTAGCTCTAGACCACGTGCGCCCAC
GTGCGCCCAC-3′ containing SpeI and XbaI restriction sites,
respectively. After restrictive digestion with SpeI and XbaI, the
hTERT promoter fragment was successfully inserted into the
linearized plasmid to form the pCDH-hTERT-Fth1-3FLAG-
Puro vector.
Lentiviral vectors were produced by cotransfecting 293T
cells with three plasmids (the reconstructed plasmids pCDH-
hTERT-Fth1-3FLAG-Puro or pCDH-CMV-Fth1-3FLAG-
Puro, the packaging plasmids pCD/NL-BH*DDD and
pLTR-G) at a ratio of 3:2:1. Forty-eight hours after transfec-
tion, the viruses were collected and concentrated. The con-
structed lentiviral vectors were named Lenti-hTERT-Fth1-
3FLAG-Puro and Lenti-CMV-Fth1-3FLAG-Puro.
Culture of cells
Five human cell lines were chosen for this study. Lung carci-
noma A549, ovarian carcinoma SKOV3, embryonic kidney
293T, osteosarcoma U2OS and primary periodontal ligament
fibroblast (HPDLF) cells were all obtained from the central
laboratory of Xin Qiao Hospital (Chongqing, China). A549,
SKOV3, 293T and HPDLF cells were maintained in DMEM
medium (Gibco), and U2OS cells were cultured in McCoy’s
5Amedium (Gibco). All media were supplemented with 10%
fetal bovine serum (Gibco) and 100 U/ml of penicillin–strep-
tomycin (Gibco). Immunofluorescence staining and western
blotting were performed as described below to determine the
presence of hTERT protein in all cell lines.
Lentivirus transfection
Cells were incubated with Lenti-hTERT-Fth1-3FLAG-Puro
and Lenti-CMV-Fth1-3FLAG-Puro in the presence of
polybrene (Sigma, 5–8 μg/ml) for 24 h [11]. The expression
of FLAG-tagged Fth in all cells was analysed by immunoflu-
orescence staining and an enzyme-linked immunosorbent as-
say (ELISA) as described below. Iron accumulation was de-
termined by Prussian blue iron staining and by using a total
iron assay kit as described below.
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Western blot analysis
Cells (2×106) were lysed on ice in 200 μl RIPA buffer with
protease inhibitor (Sigma). The concentration of the collected
cellular protein was evaluated by the bicinchoninic acid
(BCA) assay according to the manufacturer’s instructions
(Pierce Biotechnology) [12], and ca. 15 μg of the protein
samples was loaded onto 10 % gels for SDS–PAGE. The
proteins were then transferred onto PVDF membranes for
blotting. The membranes were blocked in 5 % bovine serum
albumin for 2 h and then incubated overnight at 4 °C with
rabbit anti-TERT monoclonal antibody (1:1000, Abcam) or
mouse anti-β-actin monoclonal antibody (1:1000, Abcam).
After thoroughly washing with Tris-buffered saline with
0.1 % Tween 20 (0.1 % TBST), the membranes were incubat-
ed with horseradish peroxidase-conjugated goat anti-rabbit or
anti-mouse IgG (1:1000, Santa Cruz) for 1 h. The protein
bands were visualized by enhanced chemiluminescent (ECL)
agents (Pierce Biotechnology) following the manufacturer’s
protocol.
Immunofluorescence staining
Cells were cultured in confocal petri dishes (NEST
Biotechnology) and rinsed with phosphate buffered saline
(PBS) pH 7.4 before examination. Following fixation in 4 %
paraformaldehyde (PFA) for 10 min, the cells were blocked
with 5 % normal goat serum in PBS at 37 °C for 30 min. To
examine hTERT protein expression, the cells were incubated
with rabbit anti-hTERT monoclonal antibody (1:500, Abcam)
overnight at 4 °C and then visualized with Alexa Flour 488-
conjugated goat anti-rabbit antibody (1:1000, Beyotime). To
examine FLAG protein expression, the cells were incubated
with mouse anti-FLAGmonoclonal antibody (1:1000, Sigma)
overnight at 4 °C and then visualized with Alexa Flour 555-
conjugated goat anti-mouse antibody (1:1000, Beyotime).
The cell nuclei were counterstained with DAPI (1:1000,
Beyotime).
Enzyme-linked immunosorbent assay
Extracts of 106 cells were collected, and the BCA assay was
used to determine the total protein concentration of each sam-
ple. The total ferritin heavy chain (Fth) content in each cell
sample was analysed using an ELISA kit (Uscn Life Science
Inc, Wuhan, China) according to the manufacturer’s instruc-
tions. The concentration of Fth in the samples was determined
by comparing the O.D. of the samples to the standard curve.
The results are expressed as nanograms of Fth per milligram
of total protein. Values are the means±SD of three indepen-
dent experiments.
Assessment of iron accumulation
Cells were cultured in medium supplemented with ferric am-
monium citrate (FAC, 1mM, Sigma) for 48 h and thenwashed
thoroughly with PBS to remove any free iron. For Prussian
blue staining, cells were fixed in 4 % PFA for 10 min and then
incubated in Prussian blue working solution, which was pre-
pared by mixing equal parts of 1 % potassium ferric ferrocy-
anide solution and 5 % hydrochloric acid solution for 30 min
[12]. Cells were counterstained with nuclear fast red
(Beyotime) for 5 min. The iron content of all cells was further
determined by using an iron assay kit according to the manu-
facturer’s instructions (Sigma). Briefly, 2×106 cells were ho-
mogenized in cold iron assay buffer, and the cell extracts were
collected to determine their iron contents. Absorbance was
immediately measured at 593 nm. The iron content for each
sample was determined by dividing the iron content by the
number of cells (pg/cell). Three sets of samples were
measured.
Tumour models
Twelve BALB/c nude mice (male, 4 weeks old, and 16–18 g)
of specific pathogen-free grade were purchased from the
Animal Department, Third Military Medical University. We
performed experiments in accordance with the local ethics
committee of the Third MilitaryMedical University. The mice
were treated with an intraperitoneal injection of 400 μl iron
dextran (50 mg/2 ml, Zhejiang Ruian Pharmaceutical Factory,
China) every 3 days for a total of six injections. After the
fourth iron injection, the bilateral hind flanks of the mice were
subcutaneously inoculated with A549 or U2OS cells (106
cells/position) (n=6 for each tumour sample). When tumours
reached approximately 5–10 mm in diameter, each tumour
model was randomly divided into two groups (n=3). In one
group, 100 μl Lenti-hTERT-Fth1-3FLAG-Puro viral particles
(5×108 IU/ml) were intratumorally injected into the left-side
tumour and nothing into the right-side tumour. In the other
group, 100 μl Lenti-CMV-Fth1-3FLAG-Puro viral particles
(5×108 IU/ml) were injected into the left-side tumour and
100 μl PBS was injected into the right-side tumour.
Magnetic resonance imaging
Cells were grown in medium supplemented with FAC (1 mM)
for 48 h before MR imaging. After thorough washing with
PBS to remove extracellular iron, dissociating with trypsin,
and fixing in 4 % PFA for 10 min, the cells were suspended
in 1 ml PBS and transferred into 2-ml microcentrifuge tubes
(5×107 cells/tube), which were precoated with 500 μl 1 %
agarose. After the cells had settled for 20–30 min and formed
a loose pellet on the top of the agarose, MRI was performed
with a 3.0-T MR unit with a knee coil (GE Signa HDx). T2*-
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weighted images were acquired using a GRE (gradient
recalled echo) sequence with the following parameters: TR
(repetition time)=400 ms, TE (echo time)=12 ms, flip an-
gle = 30° and slice thickness = 1.0 mm. In a second GRE
Fig. 2 Analysis of FLAG-tagged
Fth expression in cells transfected
with or without lentiviral vector. a
Immunofluorescence staining of
cells with anti-FLAG antibody.




images of A549, SKOV3 and
293T cells but not U2OS or
HPDLF cells. Red fluorescence
represents FLAG-tagged protein;
blue fluorescence represents cell
nuclei. Scale bar 50μm. bELISA
for Fth protein in all cell types. In
A549, SKOV3 and 293T cells,
but not U2OS or HPDLF cells,
transfected with Lenti-hTERT-
Fth1-3FLAG-Puro, Fth protein
level was significantly increased
compared to the untransfected
cells. Error bars indicate standard
deviations of triplicate samples.
*p value was statistically
significant (p< 0.05). hTERT
Lenti-hTERT-Fth1-3FLAG-Puro-




Fig. 1 Expression of hTERT protein in cell lines. a Immunofluorescence
staining in cells with anti-hTERT antibody. In immunofluorescence im-
ages, hTERT was visible in A549, SKOV3 and 293T cells but not in
U2OS or HPDLF cells. Green fluorescence represents hTERT proteins;
blue fluorescence represents cell nuclei. Scale bar 50μm. bWestern blots
for hTERT protein using anti-hTERT antibody (β-actin was used as an
internal control). hTERT protein was detected in A549, SKOV3 and
293T cells but not in U2OS or HPDLF cells
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acquisition, R2* measurements were derived from eight im-
ages using the following parameters: TR=1000ms, TE=2.5–
27.0 ms (8 echoes) and slice thickness=2.2 mm.
Tumours were imaged 15 days after virus injection using a
1.5-T MR scanner (GE Signa HDx). Mice were anaesthetized
with 2 % sodium pentobarbital and placed in a wrist coil. T2-
weighted images of tumours were obtained using an FSE (fast
spin echo) sequence (TR=2000ms, TE=47.5 ms, FOV (field
of view) = 6 × 6 cm and slice thickness = 2.0 mm). T2*-
weighted images were obtained using a GRE sequence
(TR = 540 ms, TE = 10 ms, FOV = 6 × 6 cm and slice
thickness=2.0 mm).
Immunohistochemistry and histology of tumour tissues
After MR scanning, mice were decapitated, and tumours were
removed and fixed with 4 % PFA. Each tumour was embed-
ded in OCT (optical cutting temperature) and sectioned using
a cryostat microtome. Prepared frozen sections (4μm in thick-
ness) were used for immunofluorescence staining and
Prussian blue iron staining to determine FLAG-tagged Fth
expression and iron accumulation in tumour tissues, respec-
tively, as described above.
Statistical analysis
Data are presented as the mean±SD. Significance tests were
performed using one-way ANOVA (Graphpad Prism version
5.0). Differences were considered significant at p values of
less than 0.05.
Results
Expression of hTERT proteins in cell lines
By performing immunofluorescence staining and western blot
analysis, we confirmed the expression of hTERT proteins in
A549, SKOV3 and 293T cell lines; whereas, no hTERT pro-
tein was detected in U2OS or HPDLF cell lines (Fig. 1). These
results are consistent with previously published work [13–16].
As the expression of hTERT protein is good indicator of tel-
omerase activity [2], A549, SKOV3 and 293T cell lines were
considered telomerase-positive, while U2OS and HPDLF cell
lines were considered telomerase-negative in this study.
hTERT promoter drives Fth expression
in telomerase-positive cells
After transfection with Lenti-hTERT-Fth1-3FLAG-Puro, im-
munofluorescence staining showed that FLAG-tagged protein
was present in telomerase-positive cells but absent in
telomerase-negative cells. In contrast, FLAG-tagged protein
was present in all five cell lines transfected with Lenti-CMV-
Fth1-3FLAG-Puro and absent in all five untransfected cell
lines (Fig. 2a). Analysis by ELISA showed that Fth protein
content in Lenti-hTERT-Fth1-3FLAG-Puro-transfected
telomerase-positive cells was significantly greater (4421–
Fig. 3 Analysis of iron accumulation in cells treated with FAC (1mM) for
48 h. a Prussian blue staining of cells showed positive results in A549,
SKOV3 and 293T cells, but not in U2OS or HPDLF cells, transfected
with Lenti-hTERT-Fth1-3FLAG-Puro. Scale bar 5 μm. b Average iron
content in each cell sample measured by an iron assay kit. A549, SKOV3
and 293T cells, but not U2OS or HPDLF cells, transfected with Lenti-
hTERT-Fth1-3FLAG-Puro accumulated more iron than the untransfected
cells. Error bars indicate standard deviations of triplicate samples. *p
value was statistically significant (p< 0.05). hTERT Lenti-hTERT-Fth1-
3FLAG-Puro-transfected cells, CMV Lenti-CMV-Fth1-3FLAG-Puro-
transfected cells, WTwild-type cells
Eur Radiol (2016) 26:4089–4097 4093
5039 ng/mg of total protein) than that in untransfected
telomerase-positive cells (246–388 ng/mg of total protein)
(p<0.05, n=3). In contrast, there was no remarkable differ-
ence between the Lenti-hTERT-Fth1-3FLAG-Puro-
transfected telomerase-negative cells and the untransfected
telomerase-negative cells (270–409 ng/mg of total protein)
(p>0.05, n=3) (Fig. 2b). By comparison, both telomerase-
positive and telomerase-negative cells transfected with
Lenti-CMV-Fth1-3FLAG-Puro contained greater Fth protein
than their untransfected counterparts (p<0.05, n=3) (Fig. 2b).
More iron was accumulated in cells with Fth expression
To verify the ability of Fth expression to augment iron storage,
Prussian blue staining was performed. Blue granules of accu-
mulated iron were detected in telomerase-positive cells but not
in telomerase-negative cells transfected with Lenti-hTERT-
Fth1-3FLAG-Puro. Moreover, blue granules were not ob-
served in any untransfected cells (Fig. 3a). The iron content
assay revealed that the iron content of Lenti-hTERT-Fth1-
3FLAG-Puro-transfected telomerase-positive cells (7.033–
7.766 pg/cell) was significantly higher than that of
untransfected telomerase-positive cells (2.152–2.712 pg/cell)
(p< 0.05, n= 3), but this difference was not observed in
telomerase-negative cells (2.740–2.914 pg/cell) (p> 0.05,
n=3) (Fig. 3b). In contrast, all cells transfected with Lenti-
CMV-Fth1-3FLAG-Puro showed blue granules and had sig-
nificantly higher iron content than their untransfected counter-
parts (p<0.05, n=3).
hTERT promoter-mediated Fth reporter gene expression
induces specific MRI contrast in telomerase-positive cells
in vitro
The T2*WI signal intensity of Lenti-hTERT-Fth1-3FLAG-
Puro-transfected telomerase-positive cells was lower than that
of untransfected telomerase-positive cells, but this difference
was not observed in telomerase-negative cells (Fig. 4a). In
comparison, all of the Lenti-CMV-Fth1-3FLAG-Puro-
transfected cells showed signal loss compared to their
untransfected counterparts (Fig. 4a). Furthermore, these signal
changes were in agreement with the increase in cellular R2*.
The R2* value of Lenti-hTERT-Fth1-3FLAG-Puro-transfected
telomerase-positive cells (110.8–134.9 s−1) was higher than
that of untransfected ones (66.83–75.61 s−1) (p<0.05), but this
difference was not observed in telomerase-negative cells
(54.28–58.84 s−1) (p>0.05) (Fig. 4b).
hTERT promoter-mediated Fth reporter gene expression
induces specific MRI contrast in telomerase-positive
tumours in vivo
A549 tumours showed hypointensity on T2*WI after in-
jection with Lenti-hTERT-Fth1-3FLAG-Puro, while the
U2OS tumours did not (Fig. 5). In contrast, both A549
and U2OS tumours showed hypointensity on T2*WI after
injection with Lenti-CMV-Fth1-3FLAG-Puro (Fig. 5).
There was no apparent difference in signal intensity be-
tween the PBS-injected tumours and the WT (wild type)
tumours (Fig. 5).
Immunohistologic analysis of tumours
Immunofluorescence staining of tumours with or without len-
tivirus injection was performed using anti-FLAG antibody.
After injection with Lenti-hTERT-Fth1-3FLAG-Puro,
FLAG-tagged Fth proteins were only expressed in A549 tu-
mours (Fig. 6). In contrast, FLAG-tagged Fth proteins were
detected in both tumour types after injection with Lenti-CMV-
Fth1-3FLAG-Puro. Accordingly, notable positive Prussian
blue staining was observed in Lenti-hTERT-Fth1-3FLAG-
Puro-injected A549 tumours and Lenti-CMV-Fth1-3FLAG-
Fig. 4 In vitro MRI analysis of cells treated with FAC (1 mM) for 48 h. a
T2*-weighted images of cells. Remarkable hypointensity was detected in
A549, SKOV3 and 293Tcells, but not U2OS or HPDLF cells, transfected
with Lenti-hTERT-Fth1-3FLAG-Puro. b R2* values of cells were
measured from R2* maps. Error bars indicate standard deviations of
R2* within three regions of interest on the parametric map. *p value
was statistically significant (p < 0.05). hTERT Lenti-hTERT-Fth1-
3FLAG-Puro-transfected cells, CMV Lenti-CMV-Fth1-3FLAG-Puro-
transfected cells, WTwild-type cells
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Puro-injected A549 and U2OS tumours, but not in other tu-
mours. These results were in line with those of the cell exper-
iments described above.
Discussion
In recent years, great efforts have been devoted to designing
molecular targeting reagents for cancer diagnosis. The re-
search focus of many studies is on conjugating exogenous
contrast agents with a specific ligand/antibody, so that the
agents target the cells of interest and, thus, alter the MR signal
intensity of those cells [17, 18]. However, there are many
limitations to this method, including the decay of receptor–
ligand or antigen–antibody binding activity in vivo, the limit-
ed retention time of exogenous contrast agents in cells due to
cellular division, and the background caused by nonspecific
uptake of exogenous contrast agents by the reticuloendothelial
system, which influences the visualization and analysis of
cancer lesions.
Ferritin possesses a superparamagnetic moment and can
shorten the T2 relaxation time of protons nearby [19]. The
use of ferritin as a reporter gene to produce endogenous con-
trast can avoid some of the limitations of exogenous contrast
agents. Cohen et al. first demonstrated that the introduced
expression of ferritin heavy chain under tetracycline (TET)
regulation resulted in an elevation of R1 and R2 relaxation
rates in C6 cells, and they detected C6 tumours expressing
ferritin heavy chain gene on T2WI [20]. Soon after, this team
generated transgenic mice expressing the ferritin heavy chain
under the control of the vascular endothelial cadherin promot-
er, and specifically visualized endothelial cells by MR
Fig. 6 Histological analyses of
tumour sections. a
Immunofluorescence staining of
FLAG protein in tumours with
anti-FLAG antibody. Red
fluorescence represents FLAG-
tagged proteins; blue fluorescence
represents cell nuclei. Scale bar
50μm. b Prussian blue staining of
iron deposits in tumour tissues.
Scale bar 10 μm. hTERT Lenti-
hTERT-Fth1-3FLAG-Puro-




Fig. 5 In vivo MRI analysis of tumours injected with vectors. T2*-
weighted imaging of tumours shows remarkable hypointensity in A549
tumours, but not U2OS tumours, injected with Lenti-hTERT-Fth1-
3FLAG-Puro and in A549 and U2OS tumours injected with Lenti-
CMV-Fth1-3FLAG-Puro. No apparent signal loss in T2-weighted
images of the tumours was observed. hTERT Lenti-hTERT-Fth1-
3FLAG-Puro-injected tumours, CMV Lenti-CMV-Fth1-3FLAG-Puro-
injected tumours, WTwild-type tumours, PBS PBS-injected tumours
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imaging [21]. To date, a variety of promoters have been ex-
plored and used to regulate target gene expression, e.g. pro-
moters selected on the basis of their potential to target cancer,
such as the prostate-specific antigen promoter [22], α-
fetoprotein promoter [23] and the prolactin promoter [24].
In the present study, we used the hTERT promoter to drive
ferritin heavy chain expression, since it is functional in the
majority of cancer cells regardless of their histological types,
but is silent in somatic or benign cells. We constructed a
FLAG-tagged ferritin heavy chain reporter gene expression
lentiviral vector Lenti-hTERT-Fth1-3FLAG-Puro and showed
that FLAG-tagged Fth was specifically expressed in
telomerase-positive cells both in vitro and in vivo. In addition,
Prussian blue staining for iron was observed in Fth-expressing
cells and tumours.With the increase in ferritin protein and iron
accumulation, the R2* value of cells was significantly in-
creased and signal loss was observed on T2*-weighted im-
ages. However, we found that the results obtained above did
not correspond very well with each other, possibly because of
the contribution of many factors to R2*, such as the mode of
nucleation of iron, the aggregation of ferritin in lysosomes
[25], different levels of promoter activity and different levels
of ferritin expression in different cell lines. As shown in Fig. 5,
signal loss was observed on GRE T2*-weighted images of
tumours with Fth reporter gene expression but not on FSE
T2-weighted images, suggesting that a GRE sequence is likely
more sensitive to iron than FSE sequence [26].
Moreover, the Fth-expressing tumours also showed hetero-
geneous signal intensity on T2*-weighted images. There are
several possible explanations for this finding: (1) the uneven
distribution of iron particles in the tumour tissues; (2) the
manner of lentivirus injection, which may cause cells near
the injection site to be transfected with more vector particles
than those distant from the injection site, resulting in a higher
ferritin expression level in the cells near the injection site; and
(3) the maldistribution of telomerase-positive cells in the le-
sions, as the hTERT promoter can only drive ferritin expres-
sion in them.
In summary, we used an MR molecular imaging technolo-
gy to specifically detect cancer cells both in vitro and in vivo.
We demonstrate for the first time that MR reporter imaging
mediated by the hTERT promoter could be a novel and broad-
spectrum imaging tool for cancer research and diagnosis.
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